ProCE Banner Activity

Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know

Slideset Download
Expert faculty discuss the latest data on using SGLT2 inhibitors to reduce HF risk in patients with T2D

Released: June 07, 2021

Expiration: June 06, 2022

No longer available for credit.

Share

Faculty

Jennifer B. Green

Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Mikhail N. Kosiborod

Mikhail N. Kosiborod, MD

Professor of Medicine
Kansas City School of Medicine
University of Missouri
Consulting Cardiologist
Division of Cardiovascular Research
Department of Cardiology
Saint Lukes Mid America Heart Institute
Kansas City, Missouri

Provided by

Provided by the Endocrine Society, in collaboration with Clinical Care Options.
ProCE Banner

Supporters

This activity is supported by an independent educational grant from

Boehringer Ingelheim and Eli Lilly

Faculty Disclosure

Primary Author

Jennifer B. Green, MD

Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Mikhail N. Kosiborod, MD

Professor of Medicine
Kansas City School of Medicine
University of Missouri
Consulting Cardiologist
Division of Cardiovascular Research
Department of Cardiology
Saint Lukes Mid America Heart Institute
Kansas City, Missouri